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Background: Acinetobacter baumannii can cause severe infections, mainly in critically ill inpatients. 
Treatment is complicated by multidrug-resistance (MDR). In Germany, to date, little is known on the 
extent of MDR in A. baumannii isolated from inpatients in German hospitals and potential factors 
influencing the emergence of MDR.  
Materials and Methods: We retrospectively analysed the data of A. baumannii isolates from the 
inpatients of four German university hospitals, tested for antimicrobial resistance with the broth dilution 
method between 2002 and 2006. We defined MDR as resistance to three or more classes of 
recommended drugs. After calculating the proportions of MDR in A. baumannii isolates, we 
investigated the association between MDR in A. baumannii and year of pathogen isolation, hospital, 
ward type, specimen and demographics. We performed descriptive analysis and multivariable logistic 
regression. Additionally, proportions of in vitro drug effectiveness against multidrug-resistant and non-
multidrugresistant A. baumannii isolates were determined. 
Results: MDR was found in 66 of 1,190 (5.6%) A. baumannii isolates and increased from 2.1% in 
2002 to 7.9% in 2006. The highest proportions of MDR were found in hospital A (8.9%), in intensive 
care units (7.3%), in isolates from blood (7.6%) and in male patients aged 60 years or older (6.6%). In 
multivariable analysis, the chance of MDR in A. baumannii isolates increased with the successive 
years of pathogen isolation (odds ratio [OR] 1.3, 95% confidence interval [CI] 1.1–1.5) and there was a 
higher risk of MDR in A. baumannii in intensive care units (OR 1.8, 95% CI 1.1–2.9). The lowest in 
vitro antibiotic resistance was found in meropenem, imipenem and ampicillin/sulbactam, with 33, 37 
and 39% for multidrugresistant and 0.4, 1 and 3% in non-multidrug-resistant A. baumannii isolates, 
respectively.  
Conclusions: The increase of MDR in A. baumannii isolates from 2002 to 2006 in four hospitals 
suggests that clinicians in Germany may expect a rising proportion of MDR in A. baumannii isolates 
among inpatients. The antimicrobial susceptibility testing of A. baumannii isolates against 
recommended drugs, combined with in-house antimicrobial resistance surveillance, is needed to 















Acinetobacter baumannii is a gram-negative organism and is considered as an emerging hospital-
acquired pathogen [1, 2]. Skin, pharyngeal or faecal colonisation can occur in 1–3% of healthy 
humans and potentially creates a patientreservoir as a source for A. baumannii infections in hospital 
environments. Infections are typically found in critically ill patients. Clinical manifestations most 
frequently include pneumonia and bloodstream infections. Attributable deaths of patients infected with 
A. baumannii range from 8 to 23% and 10 to 43% in hospitals and intensive care units (ICUs), 
respectively [3].  
 
The increasing incidence of A. baumannii infections during the past several decades can be partially 
attributed to a rising proportion of susceptible persons as a result of advanced medical support of 
critically ill and frail patients [1, 4]. Survival on dry inanimate surfaces can be between 3 days and 4 
months, depending on the strain, and contributes to the successful persistence of Acinetobacter 
infections in health care settings [5, 6]. A. baumannii has been isolated from hospital equipment, 
bedding, furniture and staff [7]. Rising rates of antimicrobial drug resistance in A. baumannii isolates 
are a matter of concern. Resistance to carbapenems – long considered as the first-choice antibiotics in 
severe A. baumannii infections – exceeded 25% in both Italy and Turkey, and was higher than 20% in 
the UK between 1997 and 2000 [7, 8]. Moreover, the emergence of multidrug-resistance (MDR) 
complicates treatment.  
 
Antimicrobial resistance varies across countries, as well as on the level of individual hospitals [7]. A 
US study collecting A. baumannii isolates from 76 centres between January 2004 and September 
2005 reported MDR in A. baumannii at 29% [9]. Large-scale surveillance data on MDR in A. 
baumannii isolates from Europe is scarce and varying definitions of MDR hamper comparability. 
Particularly in Germany, to our knowledge, no analyses on large-scale surveillance data of MDR in A. 
baumannii isolates have been published so far. The German Network 
for Antimicrobial Resistance Surveillance (GENARS) continuously collects antimicrobial resistance 
data from university hospitals using standardised test methods. Our objectives were to determine the 
proportions of and to identify potential risk factors for MDR in A. baumannii isolates. Additionally, we 
wanted to assess the in vitro antimicrobial effectiveness of the tested antibiotics against multidrug-
resistant and non-multidrug-resistant A. baumannii isolates to illustrate therapeutic options. 
 
 
Materials and Methods 
 
Inclusion Criteria for Data Analysis  
Surveillance data on the antimicrobial susceptibility of A. baumannii isolates sampled between 2002 
and 2006 were retrospectively analysed. The data originated from those six German university 
hospitals which voluntarily participated in the GENARS-project and provided susceptibility data on A. 
baumannii isolates. They were located in six of 16 German federal states (Baden-Wuerttemberg, 
Hesse, Lower Saxony, Saxony, Schleswig–Holstein and Thuringia). Exclusively, data on A. baumannii 
isolates were available; the total number of investigated clinical specimens was not accessible. We 
only included data from four of the six university hospitals, since those centres tested A. baumannii 
isolates continuously in the stated time period. The study hospitals had a capacity of 1,117 to 1,411 
beds. Only the first collected A. baumannii isolates of inpatients were taken into consideration. 
Information on the duration between hospital admission and the first sampling for A. baumannii 
isolation was not available.  
 
Antimicrobial Susceptibility Testing and Definition of MDR 
In each university hospital, antimicrobial susceptibility testing was determined using broth dilution. 
Therefore, the Micronaut® (Merlin Diagnostika, Bornheim-Hersel, Germany), the Vitek 2® 
(bioMérieux, Nürtingen, Germany) or an in-house system, following the guidelines from the German 
Institute for Standardization (DIN) 58940-8, was accepted. DIN breakpoints of susceptibility were used 
[10]. Internal quality control included the regular use of respective reference strains from the American 
Type Culture Collection (ATCC). External quality control involved participation in ring tests. We defined 
MDR as resistance to three or more classes of recommended drugs [2, 11]. If two antibiotics from one 
class were tested, both needed to be resistant in order to meet the definition. The following antibiotic 
classes were analysed: beta-lactams (ampicillin/sulbactam, piperacillin/tazobactam), carbapenems 
(meropenem, imipenem), fluoroquinolones (ciprofloxacin, levofloxacin), cephalosporins (ceftazidime, 
  




We calculated proportions of MDR in A. baumannii isolates by year of pathogen isolation (2002–2006), 
hospital (A, B, C, D), ward type (ICU, surgical ward, medical ward, ward with immunocompromised 
patients), specimen type (respiratory, blood, urine, non-specified, other) and demographics (age, sex) 
and used the chi-square test to examine possible associations between outcome and explanatory 
variables. If an explanatory variable consisted of more than two categories, the p-value signified the 
likelihood of differences within the whole group. We considered a p-value < 0.05 as statistically 
significant.  
 
For further analysis of potential risk factors for MDR in A. baumannii isolates, we used a multivariable 
logistic regression model. We chose a stepwise backward regression with a p-value of 0.2 using 
StataTM version 10.  
 
We determined the proportions of multidrug-resistant and non-multidrug-resistant A. baumannii 






A. baumannii isolates were recovered from 1,190 inpatients. The median age was 52 years and 44% 
were female. On average, the number of isolates tested for antimicrobial susceptibility was 238 per 
year, 298 per hospital, 298 per ward type and 238 per specimen type (Table 1).  
 
MDR was found in 66 of 1,190 (5.6%, 95% confidence interval [CI] 4.2–6.8%) analysed A. baumannii 
isolates and increased from 2.1% (95% CI 0.05–4.1%) in 2002 to 7.9% (95% CI 4.5–11.3%) in 2006. 
Proportions of MDR in A. baumannii isolates did not rise in all hospitals alike. MDR in A. baumannii 
isolates increased five-fold between 2002 and 2006 in hospitals A and B and two-fold in hospital D. In 
one of the hospitals, 11.5% (95% CI 0.0–24.7%) of A. baumannii isolates were multidrug-resistant in 
2003 and no multidrug-resistant isolates were found in the other years studied (Figure 1).  
 
The highest proportions of MDR were found in hospital A (8.9%, 95% CI 5.9–12.0%), in intensive care 
units (7.3%, 95% CI 5.0–9.7%), in isolates from blood (7.6%, 95% CI 3.0–12.1%) and in male patients 
aged 60 years or older (6.6%, 95% CI 3.9–9.3%). Only the differences in the proportions of MDR in A. 
baumannii isolates by university hospital (p < 0.01) (Table 2) reached statistical significance.  
 
Four (0.3%, 95% CI 0.0–0.7%) A. baumannii isolates were resistant to all of the tested drugs. They 
exclusively originated from patients of ICUs in 2004 and 2006. Two isolates came from the same ICU 
in hospital B and were tested within 1 month of each other.  
 
In multivariable analysis, we identified an increasing risk of MDR in A. baumannii isolates over time of 
pathogen isolation (odds ratio [OR] 1.3, 95% CI 1.1–1.5) and a higher risk of MDR in A. baumannii 
isolates in ICUs (OR 1.8, 95% CI 1.1–2.9). The chance of finding MDR in A. baumannii isolates was 
lower in hospital D (OR 0.5, 95% CI 0.3–0.9) (Table 3). Hospital D did not differ from the other 
hospitals regarding year of pathogen isolation, age of patients, ward types or specimen taken.  
 
Antimicrobial Resistance of Multidrug-Resistant and Non-Multidrug-Resistant A. baumannii Isolates 
The proportions of resistance among multidrug-resistant and non-multidrug-resistant A. baumannii 
isolates differed for all of the respectively tested drugs (p < 0.001). A. baumannii isolates showed the 
lowest antibiotic resistance against meropenem, imipenem and ampicillin/sulbactam in multidrug-
resistant isolates (33, 37 and 39%, respectively) and non-multidrug-resistant isolates (0.4, 1 and 3%, 










We found higher MDR proportions in A. baumannii isolates from inpatients in ICUs. The proportions of 
MDR in A. baumannii isolates increased from 2002 to 2006. In hospital D, the chances were lower for 
inpatients to have a multidrug-resistant A. baumannii isolate. We did not find any associations 
between MDR in A. baumannii isolates and specimen types or demographics.  
 
Higher proportions of MDR in A. baumannii isolates among patients in ICUs were also found in other 
studies and can be explained by a more frequent use of invasive procedures like catheterisation or 
mechanical ventilation, 
a more common use of antibiotics and a higher proportion of critically ill patients compared to other 
ward types [12].  
 
Our results indicate that clinicians in Germany may expect a rising proportion of MDR in A. baumannii 
isolates among inpatients. The acquisition of resistance, exchange of genetic elements coding for 
resistances and the ability of A. baumannii isolates to persist and multiply in hospital environments 
may attribute to this time trend.  
 
After a revision of possible differences between the four hospitals, a specific reason for a lower chance 
of MDR in hospital D could not be elucidated. Results from a descriptive analysis showed a lower 
proportion of multidrug-resistant A. baumannii isolates in hospital C compared to hospital D. In 
multivariable analysis, however, A. baumannii isolates detected in patients from hospital D had the 
lowest chance of being multidrug-resistant. The reason for this might be the sample size, which was 
103 isolates in hospital C and 475 isolates in hospital D. 
 
The results from our data suggest that appropriate antimicrobial therapy of multidrug-resistant A. 
baumannii isolates could be achieved by the use of meropenem, imipenem or ampicillin/sulbactam. 
However, evidence from in vitro testing does not always result in clinical efficacy.  
 
Limitations of our study include the low number of hospitals from which the data were retrieved. 
Although the hospitals are located in four different federal states, they are not representative of the 34 
existing university hospitals in Germany.  
 
Since we lack clinical information, no differentiation of colonised and infected inpatients was possible. 
As the genotyping of A. baumannii isolates was not performed, and antibiotyping is not as 
discriminatory [13], possibly, existing outbreaks could not be determined.  
 
Our analyses show the proportions of MDR in a large number of tested A. baumannii isolates from four 
German university hospitals and the proportions of antimicrobials in vitro still effective. Although the 
proportion of multidrug-resistant A. baumannii isolates we found was rather low compared to the 
results from the study performed in the US by Sunenshine et al. in 2007 [12], the increase of MDR 
over time is an alarm signal to be taken seriously. The potential of A. baumannii isolates to colonise 
humans and to persist in hospital environments for many weeks can lead to outbreaks in hospitalised 
patients. MDR limits therapeutic success.  
 
Every case of multidrug-resistant A. baumannii colonisation or infection should result in timely 
infection- control measures to prevent perpetuation and human-tohuman transmission [7]. The 
identification of a common source should be prompted and include targeted screening of potentially 
colonised or infected contact persons, such as health care workers, and sampling of the hospital 
environment, particularly in ICUs [13]. Considerations in the control and treatment of nosocomial 
infections due to multidrug-resistant A. baumannii isolates were published by Urban et al. [14], such as 
the daily review of antibiotic susceptibility of all clinical isolates. 
 
According to §23 of the German Protection Against Infection Act [15], the heads of hospitals and 
institutions for outpatient surgery are obliged to continuously record and evaluate nosocomial 
infections and the appearance of pathogens with special resistances and multiple resistances in a 
separate document. These records shall be kept for 10 years and the competent health office shall be 
given permission to inspect the records on request.  
 
We recommend that hospitals set up an in-houseantimicrobial resistance surveillance system, 
including the assessment of relevant clinical parameters and to perform routine antimicrobial 
  
susceptibility testing of A. baumannii isolates to guide the selection of empirical antibiotic therapy at 
the local level and to control the spread of MDR in A. baumannii isolates. Hospitals need to be a safe 
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Tables and Figures 
 
Table 1. Numbers (n) and proportions (%) of Acinetobacter baumannii isolates detected among 






































Table 2. Numbers (n) and proportions (%) of multidrug-resistance (MDR) in A. baumannii isolates by 







Table 3. Multivariable analysis of factors associated with MDR in A. baumannii isolates in four 













Figure 1. Proportions of multidrug-resistance (MDR) in Acinetobacter baumannii isolates by year of 
isolation and university hospital, Germany, 2002–2006. In total, 66 of 1,190 (5.6%) A. baumannii 







Figure 2. In vitro antimicrobial resistance of multidrug-resistant and non-multidrug-resistant A. 
baumannii isolates in four university hospitals, Germany, 2002–2006. 
 
 
 
  
